Literature DB >> 7888208

Splicing variability in HIV type 1 revealed by quantitative RNA polymerase chain reaction.

M Neumann1, J Harrison, M Saltarelli, E Hadziyannis, V Erfle, B K Felber, G N Pavlakis.   

Abstract

A quantitative RNA-polymerase chain reaction (PCR) method able to detect the majority of mRNAs produced by human immunodeficiency virus type 1 (HIV-1) was developed and used to study expression of different HIV-1 clones in human cells. Amplified mRNAs were compared to known cDNA standards. This comparison permitted the optimization of PCR conditions and eliminated the generation of artifactual PCR bands. The use of RNA and cDNA standards demonstrated that the RNA amplification is linear within the tested range and suggested that it can be used to quantitate individual mRNAs. The results demonstrate the overall conservation of splicing in different HIV-1 clones. Although, in general, splicing was conserved, extensive qualitative and quantitative variability was observed in different HIV-1 clones. This variability is likely one determinant of the biological characteristics of the different HIV-1 clones, and demonstrates a great plasticity of the HIV-1 genome. The described RNA-PCR methodology was used for the study of HIV-1 expression in unstimulated peripheral blood mononuclear cells (PBMCs) of infected individuals. In general, the same mRNAs were identified in HIV-infected cultured cell lines and in unstimulated PBMCs. Analysis of a variant band found after amplification of PBMC RNA from an HIV-infected individual revealed a new splice site for the generation of Rev/Nef-encoding mRNAs. The availability of a sensitive, rapid, and essentially quantitative method to examine the major HIV-1 mRNAs will facilitate the detailed analysis of HIV-1 expression in human cells.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7888208     DOI: 10.1089/aid.1994.10.1531

Source DB:  PubMed          Journal:  AIDS Res Hum Retroviruses        ISSN: 0889-2229            Impact factor:   2.205


  24 in total

1.  The synthetic immunomodulator murabutide controls human immunodeficiency virus type 1 replication at multiple levels in macrophages and dendritic cells.

Authors:  E C Darcissac; M J Truong; J Dewulf; Y Mouton; A Capron; G M Bahr
Journal:  J Virol       Date:  2000-09       Impact factor: 5.103

2.  Selective regulation of human immunodeficiency virus-infected CD4(+) lymphocytes by a synthetic immunomodulator leads to potent virus suppression in vitro and in hu-PBL-SCID mice.

Authors:  G M Bahr; E C Darcissac; N Castéran; C Amiel; C Cocude; M J Truong; J Dewulf; A Capron; Y Mouton
Journal:  J Virol       Date:  2001-08       Impact factor: 5.103

3.  Transcription-dependent nuclear-cytoplasmic trafficking is required for the function of the von Hippel-Lindau tumor suppressor protein.

Authors:  S Lee; M Neumann; R Stearman; R Stauber; A Pause; G N Pavlakis; R D Klausner
Journal:  Mol Cell Biol       Date:  1999-02       Impact factor: 4.272

4.  Nuclear transport of human immunodeficiency virus type 1, visna virus, and equine infectious anemia virus Rev proteins: identification of a family of transferable nuclear export signals.

Authors:  B E Meyer; J L Meinkoth; M H Malim
Journal:  J Virol       Date:  1996-04       Impact factor: 5.103

5.  A splice hepadnavirus RNA that is essential for virus replication.

Authors:  S Obert; B Zachmann-Brand; E Deindl; W Tucker; R Bartenschlager; H Schaller
Journal:  EMBO J       Date:  1996-05-15       Impact factor: 11.598

6.  Identification of a key target sequence to block human immunodeficiency virus type 1 replication within the gag-pol transframe domain.

Authors:  S Sei; Q E Yang; D O'Neill; K Yoshimura; K Nagashima; H Mitsuya
Journal:  J Virol       Date:  2000-05       Impact factor: 5.103

7.  Heterozygosity for a defective gene for CC chemokine receptor 5 is not the sole determinant for the immunologic and virologic phenotype of HIV-infected long-term nonprogressors.

Authors:  O J Cohen; M Vaccarezza; G K Lam; B F Baird; K Wildt; P M Murphy; P A Zimmerman; T B Nutman; C H Fox; S Hoover; J Adelsberger; M Baseler; J Arthos; R T Davey; R L Dewar; J Metcalf; D J Schwartzentruber; J M Orenstein; S Buchbinder; A J Saah; R Detels; J Phair; C Rinaldo; J B Margolick; G Pantaleo; A S Fauci
Journal:  J Clin Invest       Date:  1997-09-15       Impact factor: 14.808

8.  Dynamics and modulation of human immunodeficiency virus type 1 transcripts in vitro and in vivo.

Authors:  P Bagnarelli; A Valenza; S Menzo; R Sampaolesi; P E Varaldo; L Butini; M Montroni; C F Perno; S Aquaro; D Mathez; J Leibowitch; C Balotta; M Clementi
Journal:  J Virol       Date:  1996-11       Impact factor: 5.103

9.  Decreased human immunodeficiency virus type 1 plasma viremia during antiretroviral therapy reflects downregulation of viral replication in lymphoid tissue.

Authors:  O J Cohen; G Pantaleo; M Holodniy; S Schnittman; M Niu; C Graziosi; G N Pavlakis; J Lalezari; J A Bartlett; R T Steigbigel
Journal:  Proc Natl Acad Sci U S A       Date:  1995-06-20       Impact factor: 11.205

10.  Direct participation of Sam68, the 68-kilodalton Src-associated protein in mitosis, in the CRM1-mediated Rev nuclear export pathway.

Authors:  Jinliang Li; Ying Liu; Byung Oh Kim; Johnny J He
Journal:  J Virol       Date:  2002-08       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.